First and second-line treatments in metastatic renal cell carcinoma
Background and objective The treatment landscape for metastatic renal cell carcinoma
(mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of …
(mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of …
Treatment landscape of renal cell carcinoma
YW Chen, L Wang, J Panian, S Dhanji… - … Treatment Options in …, 2023 - Springer
Opinion Statement The treatment landscape of renal cell carcinoma (RCC) has evolved
significantly over the past three decades. Active surveillance and tumor ablation are …
significantly over the past three decades. Active surveillance and tumor ablation are …
Defining oligometastatic state in uro-oncological cancers
Defining oligometastatic state among urological tumors reflecting their distinct biological and
clinical behavior is crucial to establish a sound framework for future clinical trials, and to …
clinical behavior is crucial to establish a sound framework for future clinical trials, and to …
Adjuvant immunotherapy for locally advanced renal cell carcinoma
M Alevizakos, D McDermott - Expert Opinion on Biological Therapy, 2023 - Taylor & Francis
Introduction Locally advanced renal cell carcinoma (RCC) presents a therapeutic challenge
due to 20–40% relapse risk post-nephrectomy. There has been substantial interest in …
due to 20–40% relapse risk post-nephrectomy. There has been substantial interest in …
[HTML][HTML] A case of metastatic renal cell carcinoma to the maxillary sinus initially presenting as recurrent epistaxis
JP Mehr, KA Blum, WS Jones, N Maithel… - JU Open …, 2023 - journals.lww.com
Metastatic neoplasms to the sinonasal tract are rare. Here, we report the case of a 74-year-
old woman with no notable oncological history, presenting to the emergency department …
old woman with no notable oncological history, presenting to the emergency department …
Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma
Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom
surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has …
surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has …
晚期肾透明细胞癌系统性治疗中国专家共识(2024 版).
姚欣， 周芳坚， 李长岭 - Chinese Journal of Oncology, 2024 - search.ebscohost.com
肾细胞癌约占成人恶性肿瘤的2%~ 3%, 世界范围内男女患者发病比例约为1.5∶ 1,
各年龄段均可发病, 60~ 70 岁为高发年龄段, 发病中位年龄约为64 岁. 目前肾癌的病因尚未明确 …
各年龄段均可发病, 60~ 70 岁为高发年龄段, 发病中位年龄约为64 岁. 目前肾癌的病因尚未明确 …
Metastasis-directed therapy in oligometastatic and oligoprogressive renal cell carcinoma
MDT holds promise in treating RCC by offering symptom relief, improving quality of life, and
potentially delaying systemic therapy. However, the long-term benefits, particularly …
potentially delaying systemic therapy. However, the long-term benefits, particularly …
[HTML][HTML] Active Surveillance in Metastatic Renal Cell Carcinoma
N Beecroft, TD Gauntner, R Upadhyay… - Journal of Kidney …, 2024 - ncbi.nlm.nih.gov
Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with a variable clinical
course. While therapies for treatment of this condition have progressed, they are not without …
course. While therapies for treatment of this condition have progressed, they are not without …
Impact of Preoperative Systemic Therapy on Cytoreductive Nephrectomy Outcomes in the National Surgical Quality Improvement Program (NSQIP)
Introduction Management of metastatic renal cell carcinoma (mRCC) is highly individualized
and often involves cytoreductive nephrectomy (CN) and systemic therapy (ST). The optimal …
and often involves cytoreductive nephrectomy (CN) and systemic therapy (ST). The optimal …